Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans

Science Translational Medicine

Volumn 8, Issue 323, 2016, Pages

  Reyes Soffer, Gissette ^a   Moon, Byoung ^a   Hernandez Ono, Antonio ^a   Dionizovick Dimanovski, Marija ^a   Jimenez, Jhonsua ^a   Obunike, Joseph ^b   Thomas, Tiffany ^a   Ngai, Colleen ^a   Fontanez, Nelson ^a   Donovan, Daniel S ^a   Karmally, Wahida ^a   Holleran, Stephen ^a   Ramakrishnan, Rajasekhar ^a   Mittleman, Robert S ^c,d   Ginsberg, Henry N ^a  

^a Columbia University College of Physicians and Sur ^*  (United States)

^b NEW YORK CITY COLLEGE OF TECHNOLOGY   (United States)

^c GENZYME CORPORATION   (United States)

^d Ironwood Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; INTERMEDIATE DENSITY LIPOPROTEIN; ISOTOPE; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; MIPOMERSEN; SMALL INTERFERING RNA; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; APOB PROTEIN, MOUSE; APOLIPOPROTEIN B; OLIGONUCLEOTIDE; VERY LOW DENSITY LIPOPROTEIN TRIGLYCERIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FATTY LIVER; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN SYNTHESIS; VOLUNTEER; ADOLESCENT; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMISTRY; CLINICAL TRIAL; GENETICS; HEP-G2 CELL LINE; LIVER; METABOLISM; MIDDLE AGED; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; FEMALE; HEALTHY VOLUNTEERS; HEP G2 CELLS; HUMANS; LIPOPROTEINS, IDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; LIVER; MALE; MICE; MIDDLE AGED; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RNA, SMALL INTERFERING; TRIGLYCERIDES; YOUNG ADULT;

EID: 84970938026     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aad2195     Document Type: Article

References (49)

1. M. J. Chapman, H. N. Ginsberg, P. Amarenco, F. Andreotti, J. Borén, A. L. Catapano, O. S. Descamps, E. Fisher, P. T. Kovanen, J. A. Kuivenhoven, P. Lesnik, L. Masana, B. G. Nordestgaard, K. K. Ray, Z. Reiner, M.-R. Taskinen, L. Tokgözoglu, A. Tybjærg-Hansen, G. F. Watts; European Atherosclerosis Society Consensus Panel, Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management. Eur. Heart J. 32, 1345-1361 (2011).
2. M. Adiels, S.-O. Olofsson, M.-R. Taskinen, J. Borén, Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Artheroscler. Thromb. Vasc. Biol. 28, 1225-1236 (2008).
3. D. C. Chan, P. H. R. Barrett, G. F. Watts, Lipoprotein transport in the metabolic syndrome: Pathophysiological and interventional studies employing stable isotopy and modelling methods. Clin. Sci. 107, 233-249 (2004).
4. Cholesterol Treatment Trialists' (CTT) Collaboration, C. Baigent, L. Blackwell, J. Emberson, L. E. Holland, C. Reith, N. Bhala, R. Peto, E. H. Barnes, A. Keech, J. Simes, R. Collins, Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 376, 1670-1681 (2010).
5. M. S. Brown, J. L. Goldstein, A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34-47 (1986).
6. E. S. Stroes, P. D. Thompson, A. Corsini, G. D. Vladutiu, F. J. Raal, K. K. Ray, M. Roden, E. Stein, L. Tokgözoʇlu, B. G. Nordestgaard, E. Bruckert, G. De Backer, R. M. Krauss, U. Laufs, R. D. Santos, R. A. Hegele, G. K. Hovingh, L. A. Leiter, F. Mach, W. März, C. B. Newman, O.Wiklund, T. A. Jacobson, A. L. Catapano, M. J. Chapman, H. N. Ginsberg; European Atherosclerosis Society Consensus Panel, Statin-associated muscle symptoms: Impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J. 36, 1012-1022 (2015).
7. A. K. Gitt, H. Drexel, J. Feely, J. Ferrières, J. R. Gonzalez-Juanatey, K. K. Thomsen, L. A. Leiter, P. Lundman, P. M. da Silva, T. Pedersen, D. Wood, C. Jünger, P. S. Dellea, V. Sazonov, F. Chazelle, J. J. P. Kastelein; DYSIS Investigators, Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur. J. Prev. Cardiol. 19, 221-230 (2012).
8. M. Cuchel, E. A. Meagher, H. du Toit Theron, D. J. Blom, A. D. Marais, R. A. Hegele, M. R. Averna, C. R. Sirtori, P. K. Shah, D. Gaudet, C. Stefanutti, G. B. Vigna, A. M. E. Du Plessis, K. J. Propert, W. J. Sasiela, L. T. Bloedon, D. J. Rader; Phase 3 HoFH Lomitapide Study investigators, Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: A single-arm, open-label, phase 3 study. Lancet 381, 40-46 (2013).
9. F. J. Raal, R. D. Santos, D. J. Blom, A. D. Marais, M.-J. Charng, W. C. Cromwell, R. H. Lachmann, D. Gaudet, J. L. Tan, S. Chasan-Taber, D. L. Tribble, J. D. Flaim, S. T. Crooke, Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebocontrolled trial. Lancet 375, 998-1006 (2010).
10. R. G. Lee, W. Fu, M. J. Graham, A. E. Mullick, D. Sipe, D. Gattis, T. A. Bell, S. Booten, R. M. Crooke, Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein. J. Lipid Res. 54, 602-614 (2013).
11. A. S. Wierzbicki, T. Hardman, W. T. Prince, Future challenges for microsomal transport protein inhibitors. Curr. Vasc. Pharmacol. 7, 277-286 (2009).
12. M. Cuchel, L. T. Bloedon, P. O. Szapary, D. M. Kolansky, M. L. Wolfe, A. Sarkis, J. S. Millar, K. Ikewaki, E. S. Siegelman, R. E. Gregg, D. J. Rader, Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med. 356, 148-156 (2007).
13. R. M. Crooke, M. J. Graham, K. M. Lemonidis, C. P. Whipple, S. Koo, R. J. Perera, An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res. 46, 872-884 (2005).
14. M. E. Visser, F. Akdim, D. L. Tribble, A. J. Nederveen, T. J. Kwoh, J. J. P. Kastelein, M. D. Trip, E. S. G. Stroes, Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J. Lipid Res. 51, 1057-1062 (2010).
15. E. A. Stein, R. Dufour, C. Gagne, D. Gaudet, C. East, J.M. Donovan, W. Chin, D. L. Tribble, M. McGowan, Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: Results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 126, 2283-2292 (2012).
16. R. D. Santos, P. B. Duell, C. East, J. R.Guyton, P. M.Moriarty, W. Chin, R. S. Mittleman, Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur. Heart J. 36, 566-575 (2015).
17. H. N. Ginsberg, E. A. Fisher, The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism. J. Lipid Res. 50, S162-S166 (2009).
18. F. Akdim, E. S. G. Stroes, E. J. G. Sijbrands, D. L. Tribble, M. D. Trip, J.W. Jukema, J.D. Flaim, J. Su, R. Yu, B. F. Baker, M. K.Wedel, J. J. P. Kastelein, Efficacy and safety ofmipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J. Am. Coll. Cardiol. 55, 1611-1618 (2010).
19. F. Akdim, D. L. Tribble, J. D. Flaim, R. Yu, J. Su, R. S. Geary, B. F. Baker, R. Fuhr, M. K. Wedel, J. J. P. Kastelein, Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-tomoderate hyperlipidaemia. Eur. Heart J. 32, 2650-2659 (2011).
20. J. D. Horton, H. Shimano, R. L. Hamilton, M. S. Brown, J. L. Goldstein, Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. J. Clin. Invest. 103, 1067-1076 (1999).
21. J. Melish, N.-A. Le, H. Ginsberg, D. Steinberg, W. V. Brown, Dissociation of apoprotein B and triglyceride production in very-low-density lipoproteins. Am. J. Physiol. 239, E354-E362 (1980).
22. M. Adiels, M.-R. Taskinen, C. Packard, M. J. Caslake, A. Soro-Paavonen, J. Westerbacka, S. Vehkavaara, A. Häkkinen, S.-O. Olofsson, H. Yki-Järvinen, J. Borén, Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49, 755-765 (2006).
23. M. P. Caulfield, S. Li, G. Lee, P. J. Blanche, W. A. Salameh, W. H. Benner, R. E. Reitz, R. M. Krauss, Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis. Clin. Chem. 54, 1307-1316 (2008).
24. N. G. Seidah, A. Prat, The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 11, 367-383 (2012).
25. H. Campos, K. S. Arnold, M. E. Balestra, T. L. Innerarity, R. M. Krauss, Differences in receptor binding of LDL subfractions. Arterioscler. Thromb. Vasc. Biol. 16, 794-801(1996).
26. M. Tadin-Strapps, L. B. Peterson, A.-M. Cumiskey, R. L. Rosa, V. H. Mendoza, J. Castro-Perez, O. Puig, L. Zhang, W. R. Strapps, S. Yendluri, L. Andrews, V. Pickering, J. Rice, L. Luo, Z. Chen, S. Tep, B. Ason, E. P. Somers, A. B Sachs, S. R. Bartz, J. Tian, J. Chin, B. K. Hubbard, K. K. Wong, L. J. Mitnaul, siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids. J. Lipid Res. 52, 1084-1097 (2011).
27. M. S. Hamza, C. Kumar, S. M. Chia, V. Anandalakshmi, N. Boo, W. Strapps, M. Robinson, M. Caguyong, S. Bartz, M. Tadin-Strapps, A. van Gool, S.-J. Shih, Alterations in the hepatic transcriptional landscape after RNAi mediated ApoB silencing in cynomolgus monkeys. Atherosclerosis 242, 383-395 (2015).
28. R. G. Lee, J. Crosby, B. F. Baker, M. J. Graham, R. M. Crooke, Antisense technology: An emerging platform for cardiovascular disease therapeutics. J. Cardiovasc. Transl. Res. 6, 969-980 (2013).
29. J. J. P. Kastelein, M. K. Wedel, B. F. Baker, J. Su, J. D. Bradley, R. Z. Yu, E. Chuang, M. J. Graham, R. M. Crooke, Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114, 1729-1735 (2006).
30. E. A. Fisher, M. Pan, X. Chen, X. Wu, H. Wang, H. Jamil, J. D. Sparks, K. J. Williams, The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways. J. Biol. Chem. 276, 27855-27863 (2001).
31. H. N. Ginsberg, N. A. Le, J. C. Gibson, Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss. J. Clin. Invest. 75, 614-623 (1985).
32. Y. Arad, R. Ramakrishnan, H. N. Ginsberg, Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: Implications for the pathophysiology of apoB production. J. Lipid Res. 31, 567-582 (1990).
33. J. L. Dixon, H. N. Ginsberg, Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: Information obtained from cultured liver cells. J. Lipid Res. 34, 167-179 (1993).
34. A. Grefhorst, B. M. Elzinga, P. J. Voshol, T. Plösch, T. Kok, V. W. Bloks, F. H. van der Sluijs, L. M. Havekes, J. A. Romijn, H. J. Verkade, F. Kuipers, Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J. Biol. Chem. 277, 34182-34190 (2002).
35. J. D. Brunzell, w. R. Hazzard, D. Porte Jr., E. L. Bierman, Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoprotein in man. J. Clin. Invest. 52, 1578-1585 (1973).
36. D. W. Bilheimer, J. L. Goldstein, S. M. Grundy, M. S. Brown, Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia. J. Clin. Invest. 56, 1420-1430 (1975).
37. J. S. Millar, C. Maugeais, K. Ikewaki, D. M. Kolansky, P. H. R. Barrett, E. C. Budreck, R. C. Boston, N. Tada, S. Mochizuki, J. C. Defesche, J. M. Wilson, D. J. Rader, Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production. Arterioscler. Thromb. Vasc. Biol. 25, 560-565 (2005).
38. K. Nagashima, C. Lopez, D. Donovan, C. Ngai, N. Fontanez, A. Bensadoun, J. Fruchart-Najib, S. Holleran, J. S. Cohn, R. Ramakrishnan, H. N. Ginsberg, Effects of the PPARg agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J. Clin. Invest. 115, 1323-1332 (2005).
39. J. S. Millar, G. Reyes-Soffer, P. Jumes, R. L. Dunbar, E. M. deGoma, A. L. Baer, W. Karmally, D. S. Donovan, H. Rafeek, L. Pollan, J. Tohyama, A. O. Johnson-Levonas, J. A. Wagner, S. Holleran, J. Obunike, Y. Liu, R. Ramakrishnan, M. E. Lassman, D. E. Gutstein, H. N. Ginsberg, D. J. Rader, Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. J. Clin. Invest. 125, 2510-2522 (2015).
40. J. L. Dixon, S. Furukawa, H. N. Ginsberg, Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. J. Biol. Chem. 266, 5080-5086 (1991).
41. T. Ota, C. Gayet, H. N. Ginsberg, Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J. Clin. Invest. 118, 316-332 (2008).
42. P. Siri, N. Candela, Y.-L. Zhang, C. Ko, S. Eusufzai, H. N. Ginsberg, L.-S. Huang, Post-transcriptional stimulation of the assembly and secretion of triglyceride-rich apolipoprotein B lipoproteins in a mouse with selective deficiency of brown adipose tissue, obesity, and insulin resistance. J. Biol. Chem. 276, 46064-46072 (2001).
43. F. Magkos, E. Fabbrini, K. Korenblat, A. L. Okunade, B. W. Patterson, S. Klein, Reproducibility of glucose, fatty acid and VLDL kinetics and multi-organ insulin sensitivity in obese subjects with non-alcoholic fatty liver disease. Int. J. Obes. 35, 1233-1240 (2011).
44. M. K. Hellerstein, R. A. Neese, Mass isotopomer distribution analysis at eight years: Theoretical, analytic, and experimental considerations. Am. J. Physiol. 276, E1146-E1170 (1999).
45. R. Ramakrishnan, J. D. Ramakrishnan, Using mass measurements in tracer studies-a systematic approach to efficient modeling. Metabolism 57, 1078-1087 (2008).
46. N. R. Matthan, M. Raeini-Sarjaz, A. H. Lichtenstein, L. M. Ausman, P. J. H. Jones, Deuterium uptake and plasma cholesterol precursor levels correspond as methods for measurement of endogenous cholesterol synthesis in hypercholesterolemic women. Lipids 35, 1037-1044 (2000).
47. E. P. Lutz, M. Merkel, Y. Kako, K. Melford, H. Radner, J. L. Breslow, A. Bensadoun, I. J. Goldberg, Heparin-binding defective lipoprotein lipase is unstable and causes abnormalities in lipid delivery to tissues. J. Clin. Invest. 107, 1183-1192 (2001).
48. J.-F. Hocquette, B. Graulet, T. Olivecrona, Lipoprotein lipase activity and mRNA levels in bovine tissues. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 121, 201-212 (1998).
49. K.-I. Hirano, S. G. Young, R. V. Farese Jr., J. Ng, E. Sande, C. Warburton, L. M. Powell-Braxton, N. O. Davidson, Targeted disruption of the mouse apobec-1 gene abolishes apolipoprotein B mRNA editing and eliminates apolipoprotein B48. J. Biol. Chem. 271, 9887-9890 (1996).